Fig. 3
From: Artesunate shows potent anti-tumor activity in B-cell lymphoma
Tumor growth is inhibited after artesunate treatment. a Tumor growth of BL-41-luc cells was monitored based on IVIS luminescence measurements (physical units of surface radiance (photons/s/cm2/sr)) at day 0, 4, 12 and 16 of artesunate treatment (200 mg/kg/day; treatment was initiated at day four after inoculation). Tumor growth was significantly reduced in mice treated with artesunate and significant differences were seen at day 12 (P = .0045) and day 16 (P = .0050), by t test (shown is mean ± SEM, n = 10 in each group). b IVIS images of all mice at day 16. c Kaplan-Meier survival analyses is shown, based on tumor size (> 2 cm3). A significant difference in survival was observed, P < .0001 with median survival 17.5 vs 30.5 days in the control vs. artesunate treatment groups using log-rank test. Arrow indicates end of treatment